+

WO1996002572A3 - Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci - Google Patents

Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci Download PDF

Info

Publication number
WO1996002572A3
WO1996002572A3 PCT/BE1995/000068 BE9500068W WO9602572A3 WO 1996002572 A3 WO1996002572 A3 WO 1996002572A3 BE 9500068 W BE9500068 W BE 9500068W WO 9602572 A3 WO9602572 A3 WO 9602572A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide sequence
factor viii
epitopes
fragments
antigenic polypeptide
Prior art date
Application number
PCT/BE1995/000068
Other languages
English (en)
Other versions
WO1996002572A2 (fr
Inventor
Ruth Laub
Giambattista Mario Di
Original Assignee
Croix Rouge De Belgique
Ruth Laub
Giambattista Mario Di
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Croix Rouge De Belgique, Ruth Laub, Giambattista Mario Di filed Critical Croix Rouge De Belgique
Priority to EP95927598A priority Critical patent/EP0804484A1/fr
Priority to JP8504536A priority patent/JPH10506610A/ja
Priority to US08/765,837 priority patent/US6866848B2/en
Publication of WO1996002572A2 publication Critical patent/WO1996002572A2/fr
Publication of WO1996002572A3 publication Critical patent/WO1996002572A3/fr
Priority to US11/267,631 priority patent/US7981865B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une séquence polypeptidique antigénique du facteur VIII, comprise entre l'Acide Glutamique 1649 et l'Asparagine 2019, de préférence comprise entre l'Arginine 1652 et l'Arginine 1917 de la séquence polypeptidique du facteur VIII, ou comprise entre l'Alanine 108 et la Méthionine 355, ou comprise entre l'Acide Aspartique 403 et l'Acide Aspartique 725, ou comprise entre la Lysine 2085 et la Lysine 2249.
PCT/BE1995/000068 1994-07-14 1995-07-14 Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci WO1996002572A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95927598A EP0804484A1 (fr) 1994-07-14 1995-07-14 Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci
JP8504536A JPH10506610A (ja) 1994-07-14 1995-07-14 因子ｖｉｉｉの抗原ポリペプチド配列、その断片および／またはエピトープ
US08/765,837 US6866848B2 (en) 1994-07-14 1995-07-14 Antigenic polypetide sequence of factor VIII, fragments and/or epitopes there of
US11/267,631 US7981865B2 (en) 1994-07-14 2005-11-03 Antigenic fragments of human factor VIII polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9400666A BE1008491A3 (fr) 1994-07-14 1994-07-14 Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
BE9400666 1994-07-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08765837 A-371-Of-International 1995-07-14
US08/765,837 A-371-Of-International US6866848B2 (en) 1994-07-14 1995-07-14 Antigenic polypetide sequence of factor VIII, fragments and/or epitopes there of
US09/853,080 Continuation-In-Part US20020068303A1 (en) 1994-07-14 2001-05-09 Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences

Publications (2)

Publication Number Publication Date
WO1996002572A2 WO1996002572A2 (fr) 1996-02-01
WO1996002572A3 true WO1996002572A3 (fr) 1997-02-13

Family

ID=3888256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE1995/000068 WO1996002572A2 (fr) 1994-07-14 1995-07-14 Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci

Country Status (6)

Country Link
US (1) US6866848B2 (fr)
EP (1) EP0804484A1 (fr)
JP (2) JPH10506610A (fr)
BE (1) BE1008491A3 (fr)
CA (1) CA2195126A1 (fr)
WO (1) WO1996002572A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068303A1 (en) 1994-07-14 2002-06-06 Ruth Laub Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
JPH11507664A (ja) 1995-06-12 1999-07-06 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
DE59702207D1 (de) * 1996-03-08 2000-09-21 Octapharma Ag Lachen Verfahren zur eignungsprüfung von faktor viii-haltigen proteinfraktionen
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
BR0308860A (pt) * 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
MX350293B (es) * 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
WO2007065691A2 (fr) 2005-12-07 2007-06-14 Technische Universität München Petits ligands d'affinite peptidiques et peptido-mimetiques pour le facteur viii et pour des proteines similaires au facteur viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202853A2 (fr) * 1985-05-24 1986-11-26 Scripps Clinic And Research Foundation Polypeptide neutralisant l'activité de l'inhibiteur du facteur VIII et une composition thérapeutique le contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL88309A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides for use in the purification of factor viii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202853A2 (fr) * 1985-05-24 1986-11-26 Scripps Clinic And Research Foundation Polypeptide neutralisant l'activité de l'inhibiteur du facteur VIII et une composition thérapeutique le contenant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. EATON ET AL: "Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule", BIOCHEMISTRY, vol. 25, pages 8343 - 8347 *
D. SCANDELLA ET AL: "Epitope mapping of human factor VIII inhibitor antibodies by deletion analaysis of factor VIII fragments expressed by E. coli", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, WASHINGTON US, pages 6152 - 6156 *
G. VEHAR ET AL: "Structure of human factor VIII", NATURE, vol. 312, pages 337 - 342 *
P. MULIEN ET AL: "A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII", PROTEIN ENGINEERING, vol. 2, no. 4, pages 310 - 306, XP000023666 *

Also Published As

Publication number Publication date
US20030147900A1 (en) 2003-08-07
CA2195126A1 (fr) 1996-02-01
JPH10506610A (ja) 1998-06-30
JP2006316062A (ja) 2006-11-24
WO1996002572A2 (fr) 1996-02-01
EP0804484A1 (fr) 1997-11-05
BE1008491A3 (fr) 1996-05-07
US6866848B2 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
ZA9810679B (en) Antimicrobial peptides.
CA2189882A1 (fr) Vaccins contre le papillomavirus
DE69910580D1 (de) Von der telomerase abgeleitete antigene peptide
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
AU2639095A (en) Recombinant hk2 polypeptide
WO1995021252A3 (fr) Peptides derives de wd-40 et leurs utilisations
CA2158937A1 (fr) Vecteurs d'alphavirus recombinant
HU9501276D0 (en) Stabile, liophylised composition containing proteins
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
DE69534778D1 (en) Cathepsin-02-protease
EP0754229A1 (fr) L'alfamine, une proteine albuminoide serique humaine
WO1996002572A3 (fr) Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci
WO1996034964A3 (fr) Polypeptide variant hk2 stable
EP1006126A3 (fr) Peptide possedant une activité ostéogénique
WO1996041877A3 (fr) Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
BG101787A (en) Aprotinine options having improved properties
AU4545096A (en) Polypeptide fragments capable of competition with streptococcus mutans antigen i/ii
WO1996017059A3 (fr) Recepteur du domaine de fixation cellulaire de la thrombospondine
CA2071950A1 (fr) Proteine fixatrice du collagene et sa preparation
AU3711597A (en) A novel galanin receptor
CA2199403A1 (fr) Nouvelles proteines fixant la proteine kinase a (pka) et leur utilisation
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
EP0683229A3 (fr) Procédé de préparation de l'aprotinine recombinante et de variants recombinants de l'aprotinine avec une séquence N-terminale naturelle.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2195126

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995927598

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995927598

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08765837

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载